The company is commercializing novel instrumentation and services for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to the sequencing of whole genomes and ultra-deep sequencing of target genes.
Accium offers laboratory services based on its Accelerator Mass Spectrometry platform used to detect 14C/12C ratios which provided 1,000 times more sensitivity than the most sensitive method available today such as LC/MS. It is now possible to trace biomolecule delivery in healthy subjects with low attomole sensitivity.
The company has developed a proprietary formulation technology called HDDS that converts drugs that do not dissolve well in water, or hydrophobic drugs, into microparticles or nanoparticles of the drug embedded in small microspheres, such that the drug can more rapidly dissolve in water.
Digital microfluidics is a lab-on-a-chip approach based on direct, programmable micromanipulation of nanoliter volume droplets using electrical fields. Digital microfluidics enables complex, multi-step liquid handling protocols to be flexibly, scalably, and cost effectively implemented.
Affymetrix GeneChip microarray technology is the industry-standard tool for analyzing complex genetic information. The GeneChip solution consists of oligonucleotide arrays, instruments to process and analyze the arrays, and software tools to manage and mine the data.
The Ambion brand encompasses a complete range of products for researchers whose work involves RNA. These include products for the isolation, detection, quantification, amplification, and characterization of RNA.
AnaSpec, Inc. is a leading provider of integrated proteomics solutions for worldwide life science research. With a vision for innovation through synergy, AnaSpec offers expertise in three primary technologies: peptides, detection reagents, and combinatorial chemistry. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. In conjunction, AnaSpec provides premier custom services including peptide synthesis, antibody production, and assay development.
ANP's mission is to develop cutting-edge technology platforms at the nano/bio interface and apply them in market sectors such as diagnostics/biodetection, protein/drug discovery, therapeutics, chem/bio defense, and homeland security.
The company develops biomedical nanoparticle technology and products for research and treatment of human disease. They are developing NanoElectroPlex™, a proprietary tissue selective nanoparticle platform technology based on biodegradable macromolecular carriers.
ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and next generation antibodies and subunit vaccines through its proprietary Twin Cassette yeast system.